A Phase 4 interventional study of trospium chloride and oxybutynin IR in Overactive Bladder, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2016-02-26.
Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Urinary Bladder, Overactive by AbbVie — none open to participants now, none under way, none of them phase 3. Urinary Bladder, Overactive · AbbVie.
Among the 28 studies in Urinary Bladder, Overactive by AbbVie, this one is the 21st largest by enrollment of the 22 interventional ones that give a count, is one of 4 that started in 2010, is one of 9 in phase 4, and was the 17th registered.
859 studies on the registry are indexed under Urinary Bladder, Overactive; 127 are open to participants now.
Browse Urinary Bladder, Overactive studies →None of the 28 studies in Urinary Bladder, Overactive by AbbVie is open now. The open studies under Urinary Bladder, Overactive, anywhere →
Of the 74 Urinary Bladder, Overactive studies recruiting now, 44 (59%) set no upper age limit and 16 (22%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 4 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 70 across 650 interventional studies indexed under Urinary Bladder, Overactive.
Median enrollment 265 across the 22 interventional studies, 447 across the 6 observational. Of the 28 that completed or were terminated, 20 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 28 studies in Urinary Bladder, Overactive by AbbVie, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the cerebrospinal fluid levels of trospium chloride (Sanctura XR®) and oxybutynin immediate release (Oxybutynin IR) on memory performance in patients with overactive bladder and age associated memory impairment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Sanctura XR® (trospium chloride), 60mg once daily for 10 days
Drug: trospium chloride
Oxybutynin IR (oxybutynin immediate release), 5 mg three times daily for 2 days
Drug: oxybutynin IR
Oxybutynin IR placebo three times daily for 2 days
Drug: oxybutynin IR placebo
trospium chloride (60mg) once daily for 10 days
Also known as: Sanctura XR®
oxybutynin IR (5 mg) three times daily for 2 days
oxybutynin IR placebo three times daily for 2 days
Cerebral Spinal Fluid Levels of Sanctura XR® at Day 10 Post-dose
Cerebral spinal fluid levels of Sanctura XR® at Day 10 Post-dose. Cerebral spinal fluid is the fluid that surrounds the spinal cord and the inside of the brain. Samples were drawn from patients who received Sanctura XR®.
Time frame: Day 10 Post-Dose
Cerebral Spinal Fluid Levels of Oxybutynin and N-Desethyl-Oxybutynin at Day 2 Post-dose
Cerebral spinal fluid levels of Oxybutynin and N-Desethyl-Oxybutynin (metabolite of Oxybutynin) at Day 2 Post-dose. Cerebral spinal fluid is the fluid that surrounds the spinal cord and the inside of the brain. Samples were drawn from patients who received Oxybutynin IR.
Time frame: Day 2 Post-Dose
Plasma Levels of Sanctura XR® at Day 10 Post-dose
Plasma levels of Sanctura XR® at Day 10 post-dose. Plasma is the liquid component of the blood in which the blood cells are suspended. Plasma samples were collected from each patient and analyzed for the drug the patient received.
Time frame: Day 10 Post-Dose
Plasma Levels of Oxybutynin and N-Desethyl-Oxybutynin at Day 2 Post-dose
Plasma levels of Oxybutynin and N-Desethyl-Oxybutynin (metabolite of Oxybutynin) at Day 2 post-dose. Plasma is the liquid component of the blood in which the blood cells are suspended. Plasma samples were collected from each patient and analyzed for the drug the patient received.
Time frame: Day 2 Post-Dose
Change From Baseline in Total Recall Score as Measured by the Hopkins Verbal Learning Test-Revised (HVLT-R) up to Day 10
Change from Baseline in Total Recall Score as Measured by the HVLT-R up to Day 10. The HVLT-R is an instrument used to measure verbal learning and memory (recognition and recall). It consists of 3 learning trials: free recall, delayed recall, and yes/no delayed recognition. The total recall score was the sum of 3 'free recall' learning trials, and reflects the patient's ability to learn. The total score ranges from 0 (no memory) to 36 (best memory). A positive change from baseline indicates improved memory and a negative change from baseline indicates worsened memory.
Time frame: Baseline, 10 Days
Change From Baseline in Delayed Recall Score as Measured by the HVLT-R up to Day 10
Change from Baseline in Delayed Recall Score as Measured by the HVLT-R up to Day 10. The HVLT-R is an instrument used to measure verbal learning and memory (recognition and recall). It consists of 3 learning trials: free recall, delayed recall, and yes/no delayed recognition. The total recall score was the sum of 3 'free recall' learning trials, and reflects the patient's ability to learn. The total score ranges from 0 (no memory) to 12 (best memory). A positive change from baseline indicates improved memory.
Time frame: Baseline, 10 Days
Change From Baseline in Total Recall Score as Measured by the Brief Visuospatial Memory Test-Revised (BVMT-R) up to Day 10
Change from Baseline in total recall score as measured by the BVMT-R up to Day 10. The BVMT-R is an instrument used to measure visual learning and memory (recognition and recall). It consists of 3 learning trials: free recall, delayed recall, and yes/no delayed recognition trial. The total recall score is the sum of 3 free recall learning trials, and reflects the patient's ability to learn. The total score ranges from 0 (no memory) to 36 (best memory). A positive change from baseline indicates improved memory.
Time frame: Baseline, 10 Days
Change From Baseline in Delayed Recall Score as Measured by the BVMT-R up to Day 10
Change from Baseline in delayed recall score as measured by the BVMT-R up to Day 10. The BVMT-R is an instrument used to measure visual learning and memory (recognition and recall). It consists of 3 learning trials: free recall, delayed recall, and yes/no delayed recognition trial. The total recall score is the sum of 3 free recall learning trials, and reflects the patient's ability to learn. The total score ranges from 0 (no memory) to 12 (best memory). A positive change from baseline indicates improved memory.
Time frame: Baseline, 10 Days
| Milestone | Sanctura XR® | Oxybutynin IR | Oxybutynin IR Placebo |
|---|---|---|---|
| Started | 6 | 10 | 4 |
| Completed | 6 | 10 | 4 |
| Not completed | 0 | 0 | 0 |
Cerebral spinal fluid levels of Sanctura XR® at Day 10 Post-dose. Cerebral spinal fluid is the fluid that surrounds the spinal cord and the inside of the brain. Samples were drawn from patients who received Sanctura XR®.
| Nanograms (ng) per milliliter (mL) | Sanctura XR® | Oxybutynin IR | Oxybutynin IR Placebo |
|---|---|---|---|
| Cerebral Spinal Fluid Levels of Sanctura XR® at Day 10 Post-dose | NA ± NA | — | — |
Cerebral spinal fluid levels of Oxybutynin and N-Desethyl-Oxybutynin (metabolite of Oxybutynin) at Day 2 Post-dose. Cerebral spinal fluid is the fluid that surrounds the spinal cord and the inside of the brain. Samples were drawn from patients who received Oxybutynin IR.
| Nanograms (ng) per milliliter (mL) | Sanctura XR® | Oxybutynin IR | Oxybutynin IR Placebo |
|---|---|---|---|
| Oxybutynin | — | 0.0597 ± 0.0309 | — |
| N-Desethyl-Oxybutynin | — | 0.386 ± 0.235 | — |
Plasma levels of Sanctura XR® at Day 10 post-dose. Plasma is the liquid component of the blood in which the blood cells are suspended. Plasma samples were collected from each patient and analyzed for the drug the patient received.
| Nanograms (ng) per milliliter (mL) | Sanctura XR® | Oxybutynin IR | Oxybutynin IR Placebo |
|---|---|---|---|
| Plasma Levels of Sanctura XR® at Day 10 Post-dose | 1.47 ± 1.03 | — | — |
Plasma levels of Oxybutynin and N-Desethyl-Oxybutynin (metabolite of Oxybutynin) at Day 2 post-dose. Plasma is the liquid component of the blood in which the blood cells are suspended. Plasma samples were collected from each patient and analyzed for the drug the patient received.
| Nanograms (ng) per milliliter (mL) | Sanctura XR® | Oxybutynin IR | Oxybutynin IR Placebo |
|---|---|---|---|
| Oxybutynin | — | 8.80 ± 2.84 | — |
| N-Desethyl-Oxybutynin | — | 47.0 ± 11.2 | — |
Change from Baseline in Total Recall Score as Measured by the HVLT-R up to Day 10. The HVLT-R is an instrument used to measure verbal learning and memory (recognition and recall). It consists of 3 learning trials: free recall, delayed recall, and yes/no delayed recognition. The total recall score was the sum of 3 'free recall' learning trials, and reflects the patient's ability to learn. The total score ranges from 0 (no memory) to 36 (best memory). A positive change from baseline indicates improved memory and a negative change from baseline indicates worsened memory.
| Scores on a Scale | Sanctura XR® | Oxybutynin IR | Oxybutynin IR Placebo |
|---|---|---|---|
| Baseline | 22.5 ± 2.9 | 24.4 ± 3.3 | 24.0 ± 3.7 |
| Change from Baseline up to Day 10 | -0.3 ± 3.3 | -3.3 ± 5.4 | -2.0 ± 4.8 |
Change from Baseline in Delayed Recall Score as Measured by the HVLT-R up to Day 10. The HVLT-R is an instrument used to measure verbal learning and memory (recognition and recall). It consists of 3 learning trials: free recall, delayed recall, and yes/no delayed recognition. The total recall score was the sum of 3 'free recall' learning trials, and reflects the patient's ability to learn. The total score ranges from 0 (no memory) to 12 (best memory). A positive change from baseline indicates improved memory.
| Scores on a Scale | Sanctura XR® | Oxybutynin IR | Oxybutynin IR Placebo |
|---|---|---|---|
| Baseline | 8.2 ± 1.2 | 9.4 ± 2.1 | 8.8 ± 2.1 |
| Change from Baseline up to Day 10 | -1.2 ± 1.5 | -1.3 ± 1.6 | -0.3 ± 3.7 |
Change from Baseline in total recall score as measured by the BVMT-R up to Day 10. The BVMT-R is an instrument used to measure visual learning and memory (recognition and recall). It consists of 3 learning trials: free recall, delayed recall, and yes/no delayed recognition trial. The total recall score is the sum of 3 free recall learning trials, and reflects the patient's ability to learn. The total score ranges from 0 (no memory) to 36 (best memory). A positive change from baseline indicates improved memory.
| Scores on a Scale | Sanctura XR® | Oxybutynin IR | Oxybutynin IR Placebo |
|---|---|---|---|
| Baseline | 15.8 ± 6.6 | 20.3 ± 9.9 | 16.8 ± 11.3 |
| Change from Baseline up to Day 10 | 1.2 ± 7.4 | -1.1 ± 5.3 | 0.0 ± 3.5 |
Change from Baseline in delayed recall score as measured by the BVMT-R up to Day 10. The BVMT-R is an instrument used to measure visual learning and memory (recognition and recall). It consists of 3 learning trials: free recall, delayed recall, and yes/no delayed recognition trial. The total recall score is the sum of 3 free recall learning trials, and reflects the patient's ability to learn. The total score ranges from 0 (no memory) to 12 (best memory). A positive change from baseline indicates improved memory.
| Scores on a Scale | Sanctura XR® | Oxybutynin IR | Oxybutynin IR Placebo |
|---|---|---|---|
| Baseline | 6.0 ± 4.2 | 8.0 ± 3.6 | 4.5 ± 5.3 |
| Change from Baseline up to Day 10 | 0.2 ± 3.4 | -1.8 ± 3.5 | 2.3 ± 3.9 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sanctura XR® | — | 0/6 (0%) | 5/6 (83.3%) |
| Oxybutynin IR | — | 0/10 (0%) | 7/10 (70%) |
| Oxybutynin IR Placebo | — | 0/4 (0%) | 2/4 (50%) |
| Event | Sanctura XR® | Oxybutynin IR | Oxybutynin IR Placebo |
|---|---|---|---|
| HeadacheNervous system disorders | 5/6 | 5/10 | 2/4 |
| Back PainMusculoskeletal and connective tissue disorders | 4/6 | 3/10 | 1/4 |
| Pain in ExtremityMusculoskeletal and connective tissue disorders | 1/6 | 4/10 | 2/4 |
| NauseaGastrointestinal disorders | 2/6 | 2/10 | 0/4 |
| Muscle SpasmsMusculoskeletal and connective tissue disorders | 1/6 | 1/10 | 1/4 |
| Dry MouthGastrointestinal disorders | 0/6 | 2/10 | 0/4 |
| DizzinessNervous system disorders | 1/6 | 2/10 | 0/4 |
| LethargyNervous system disorders | 1/6 | 0/10 | 0/4 |
| TinnitusEar and labyrinth disorders | 1/6 | 0/10 | 0/4 |
| DiarrhoeaGastrointestinal disorders | 1/6 | 0/10 | 0/4 |
| Age, Continuous(Years) | Sanctura XR® | Oxybutynin IR | Oxybutynin IR Placebo | Total |
|---|---|---|---|---|
| Mean | 74.4 ± 6.3 | 68.3 ± 6.1 | 77.6 ± 12.3 | 72.0 ± 8.2 |
| Sex: Female, Male(Participants) | Sanctura XR® | Oxybutynin IR | Oxybutynin IR Placebo | Total |
|---|---|---|---|---|
| Female | 3 | 6 | 2 | 11 |
| Male | 3 | 4 | 2 | 9 |
The record gives a start of Aug 2010, a primary completion of Mar 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2012, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trospium chloride